MRK
MerckBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The cleanest bullish read is that April 30 results reinforced underlying demand in oncology and newer launches: KEYTRUDA remained strong, WINREVAIR kept scaling, Animal Health grew double digits, and management raised the midpoint of 2026 sales and non-GAAP EPS guidance [#8-K-2026-04-30]. The IR deck also gives MRK a better-than-generic follow-through setup because there are multiple dated milestone shots across oncology, cardiometabolic/respiratory, HIV, immunology, and ophthalmology [#IR-2026-04-30].
Posture
Constructive
Lead driver
Momentum
What changed
2 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Acquisition activity is distorting optics and increasing execution risk: Cidara created a $9.0B charge in Q1 and the planned Terns close would add an approximately $5.8B one-time charge not included in current outlook [#8-K-2026-04-30].
Momentum
62
Value
65
Sentiment
56
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $126.00 · Bull $138.00 · Bear $98.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $128.40
Why
Momentum62 · Δ7d +8.3
Value65 · Δ7d +0.5
Sentiment56 · Δ7d +9.7
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
62
34% active weight
Current posture
7d trendSoftening
Δ7d
+8.3
Δ21d
+33.7
Value
65
32% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
+0.2
Sentiment
56
33% active weight
Current posture
7d trendImproving
Δ7d
+9.7
Δ21d
+4.5
Why this grade
Composite grade B. Momentum 62.4 / Value 64.8 / Sentiment 56.1
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$284.45B
Beta
0.29
Shares Out
2.48B
P/E (TTM)
14.2
P/S (TTM)
4.15
P/FCF (TTM)
53.98
Rev YoY
+3.7%
EPS YoY
+86.4%
Gross Margin
+77.7%
Op Margin
+33.7%
Net Debt
$23.42B
Current Ratio
1.66
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology